
Opinion|Videos|March 21, 2025
Quality of Life in MPNs: Patient-Centered Factors That Shape Treatment Approaches
Author(s)Daniel Landau, MD
An expert discusses how quality-of-life assessments guide treatment strategies for patients with myeloproliferative neoplasms (MPNs).
Advertisement
Episodes in this series

Video content above is prompted by the following:
Please discuss how quality-of-life assessments guide your treatment strategies for patients with MPNs.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
3
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
4
Optimizing Second-Line Therapy in Metastatic ccRCC
5























